Physicians' Academy for Cardiovascular Education

Heart Failure, diabetes & SGLT2i: Time to change practice?

Meeting report with presentation slides and video of a PACE-CME symposium held during Heart Failure 2019 in Athens on the role of SGLT2i in the management of heart failure

Summary | Why could patients with HF and T2DM benefit from SGLT2i?

Athens, Greece – May 25, 2019

This is a summary of the presentation by prof. Subodh Verma, in which he described the potential mechanisms by which SGLT2 inhibitors (SGLT2i) mediate their beneficial effects and he presented experimental data on beneficial effects of SGLT2i in the absence of diabetes.

Summary | Real world evidence and outcomes in the management of heart failure patients with T2DM

Athens, Greece – May 25, 2019

This is a summary of the presentation by prof. Carolyn Lam, in which she shared real-world data of the Asian-HF registry and comparisons with data from other parts of the world.

Summary | The future of SGLT2i in HF: Managing patients without T2DM?

Athens, Greece – May 25, 2019

This is a summary of the presentation by prof. Adriaan Voors, in which he discussed possible future strategies with SGLT2i and gave an update on ongoing trials.

Summary | The essentials for diabetes and heart failure

Athens, Greece – May 25, 2019

This is a summary of the presentation by prof. Martin Cowie, in which he talked about what every HF cardiologist should know about treating diabetes.

Meeting Impression | Heart Failure, diabetes and SGLT2i: Time to change practice?

May 25, 2019 – Athens, Greece
May 25, 2019 – Athens, Greece

Download the meeting impression of this PACE symposium held during ESC HF 2019, in which the relevance of diabetes treatment in the management of heart failure (HF) and novel interventions to improve CV outcomes in patients with HF and diabetes were discussed

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD
Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Prof. Adriaan Voors addresses three major questions on the future of SGLT2i in HF: on routine use in T2DM and HF, use in HF without T2DM, and ongoing trials.

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore
Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

Prof. Lam talks about the global burden of HF and diabetes and presents registry data on practices and outcomes in patients with HF and diabetes.

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK
What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

What should cardiologists know about diabetes in HF patients? Martin Cowie gives an overview of how to detect and treat diabetes in HF patients.

Slides: The future of SGLT2i in HF: Managing patients without T2DM?

Slides (presentation) - June 25, 2019 - Athens, Greece - Prof. Adriaan Voors, MD, UMCG, Groningen, The Netherlands - CME symposium held during Heart Failure 2019
This lecture by prof. Adriaan Voors was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Real world practices and outcomes in the management of heart failure patients with T2DM

Slides (presentation) - June 25, 2019 - Athens, Greece - Carolyn Lam - National Heart Centre Singapore - PACE-CME symposium held during Heart Failure 2019
This lecture by prof. Carolyn Lam was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Why could patients with HF and T2DM benefit from SGLT2i?

Slides (presentation) - May 25, 2019 - Athens, Greece - Prof Subodh Verma, MD Toronto, Canada - PACE-CME symposium held during Heart Failure 2019
This lecture by prof. Subodh Verma was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada
Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.

Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.

Heart Failure, diabetes & SGLT2i: Time to change practice?
Heart Failure, diabetes & SGLT2i: Time to change practice?